ArticleTranslational vision science & technology2026
Thermosensitive Chitosan-Hyaluronic Acid Hydrogel for Sustained Betamethasone and Levofloxacin Delivery in Corneal Wound Healing.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent Advances in Extended Ocular Drug Delivery for the Ocular Surface.Molecules (Basel, Switzerland) · 2026Review
- A dual-drug chitosan-hyaluronic acid bandage contact lens accelerates corneal re-epithelialization in a rabbit mechanical debridement model.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This research designed a thermosensitive chitosan-hyaluronic acid (Ch-HA) hydrogel for the dual controlled release of betamethasone and levofloxacin to improve corneal wound healing and inhibit subsequent infections. Methods: Ch (2% w/v) and HA (10% w/v) solutions were neutralized with varying concentrations of β-glycerophosphate. The optimal formulation was characterized for gelation time, swelling, degradation, morphology, cytocompatibility, drug release profiles, and antimicrobial activity. In vivo healing was assessed in a rabbit corneal burn model using fluorescein staining, histology, and cytokine analysis. Results: Hydrogels with 35% β-glycerophosphate provided an 8-minute gelation time, low cytotoxicity, and favorable swelling/degradation profiles. In vitro release kinetics showed a release profile extending over 24 hours, reaching 49.6% for levofloxacin and 30.3% for betamethasone after 24 hours. The dual-loaded hydrogel exhibited effective antibacterial zones against Staphylococcus aureus (17.8 ± 1.5 mm), Escherichia coli (14.2 ± 1.8 mm), and Staphylococcus epidermidis (11.9 ± 0.8 mm). The antibacterial efficacy was comparable with the levofloxacin-only control for S. aureus and E. coli (P > 0.05), although slightly reduced for S. epidermidis (P < 0.05). In vivo, the Ch-HA-35-beta-levo group accelerated re-epithelialization (4.3 ± 0.6 days vs. 7.3 ± 0.6 days in untreated controls; P < 0.01). Histological analysis revealed significantly reduced epithelial thickening (56.5 ± 2.1 µm vs. 72.7 ± 2.1 µm; P < 0.001), and molecular analysis confirmed a significant downregulation of inflammatory markers, showing a 59% reduction in tumor necrosis factor-α and a 54% reduction in interleukin-6 expression (P < 0.05). Conclusions: The thermosensitive Ch-HA hydrogel demonstrated promising physicochemical properties, controlled release kinetics, effective antimicrobial efficacy, and accelerated corneal healing, offering a combined therapeutic approach to simultaneously manage inflammation and infection in corneal injuries. Translational Relevance: This instillable in situ gelling drug delivery system bridges laboratory innovation with clinical application by providing a sustained-release platform that simultaneously addresses inflammation and infection, offering a convenient once-daily regimen compared with the frequent instillation required by conventional eye drops that may improve patient compliance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.